State Street Corp Trims Stock Position in Abeona Therapeutics Inc (NASDAQ:ABEO)

State Street Corp trimmed its stake in Abeona Therapeutics Inc (NASDAQ:ABEO) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 159,295 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the period. State Street Corp’s holdings in Abeona Therapeutics were worth $1,007,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ABEO. Bank of New York Mellon Corp raised its stake in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 2,434 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after acquiring an additional 429,456 shares during the period. Simplify Asset Management Inc. bought a new position in shares of Abeona Therapeutics in the 2nd quarter worth approximately $1,732,000. abrdn plc lifted its stake in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the period. Finally, Rosalind Advisors Inc. boosted its position in shares of Abeona Therapeutics by 4.7% during the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after purchasing an additional 82,000 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Wall Street Analysts Forecast Growth

ABEO has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 25th.

Abeona Therapeutics Stock Up 6.1 %

Shares of NASDAQ:ABEO opened at $5.91 on Friday. Abeona Therapeutics Inc has a 12-month low of $3.05 and a 12-month high of $9.01. The stock has a market capitalization of $256.91 million, a price-to-earnings ratio of -2.20 and a beta of 1.44. The stock has a fifty day simple moving average of $6.01 and a two-hundred day simple moving average of $5.59. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.